| Download a sample from "The Infoshop", another service of Global Information.
|
SUMMARY
Headquartered in Pennsylvania, Mylan's roots date back to January 1961, when
Mylan Pharmaceuticals was formed; Mylan Laboratories was incorporated in
Pennsylvania in August 1970. This report provides an insight into the company,
reviewing its current business structure and activities.
Mylan produces both generic and branded pharmaceuticals for the US market;
generics through Mylan Pharmaceuticals, Mylan Technologies and UDL
Laboratories, and branded products through its Mylan Bertek Pharmaceuticals
unit. The company's generics portfolio covers a variety of dosage forms,
including immediate and extended-release oral tablets and capsules, and
transdermal patches. Additionally, it repackages and markets multi-source and
single-source products in unit dose form for the institutional marketplace.
Mylan employs around 2,800 people across its units.
- Mylan Pharmaceuticals
- Mylan Technologies
- UDL Laboratories
- Bertek Pharmaceuticals
In June 2005, Mylan reported that it will be closing its Bertek subsidiary,
and will transfer responsibility for selling Mylan Bertek's products to its
Mylan Pharmaceuticals and UDL subsidiaries. Mylan stated that the existing
Mylan Bertek business is not the type of brand platform that would enable
Mylan to fulfil its objective of becoming a more balanced specialty
pharmaceutical company. It believes that closing Mylan Bertek will streamline
its operations and result in significant cost savings.
This report provides information on the company's active product lines and
ANDA approvals, along with a review of major developments, such as M&A
activity, strategic alliances and litigation. The company's most recent
quarterly and annual financial results are illustrated with comparative
figures, charts and a detailed review of the data which allows you to track
the company's progress.
TABLE OF CONTENTS
- EXECUTIVE SUMMARY
- INTRODUCTION
- Mylan Pharmaceuticals
- Mylan Technologies
- UDL Laboratories
- Bertek Pharmaceuticals
- PRODUCTS3
- Mylan ANDA Approvals, 2002-05
- Recent product approvals
- Cyclobenzaprine
- Alprazolam
- Rabeprazole (tentative)
- Zonisamide
- Bisoprolol
- Glimepiride
- Amlodipine
- Metformin ER
- Ondansetron (tentative)
- Terbinafine
- Anagrelide capsules
- Quinapril and hydrochlorothiazide
- Olanzapine tablets (tentative)
- Modafinil tablets (tentative)
- Citalopram
- Fentanyl
- Quinapril
- Oxybutynin (tentative)
- FINANCIAL RESULTS
- Latest Full Year Highlights
- Latest Full Year Results
- Segment Data
- Generic Segment - Full Year Results, 2001-05
- Branded Segment - Full Year Results, 2001-05
- Latest Quarterly Results, Q3 2006 (quarter ended December 2005)
- Quarterly Results (US$000s)
- MAJOR DEVELOPMENTS
- Mergers, acquisitions and agreements
- Tamiflu production
- King Pharmaceuticals merger called off.
- Litigation
- Modafinil
- Mylan enters oxybutynin supply agreement with Ortho-McNeil and ALZA
- Missouri AG alleges firms involved in AWP inflation scheme
- Court denies Pfizer's summary judgement motion in amlodipine litigation
- Mylan wins oxybutynin patent litigation; ALZA to appeal
- Ortho-McNeil gains levofloxacin ruling against Mylan
- 'Authorised Generics'
- Fentanyl
- Paclitaxel
- Average wholesale price
- Mylan dismissed from AWP litigation
- CONTACT DETAILS
|
